Search results
FDA vaccine advisers vote unanimously in favor of updated COVID-19 shot for fall
WPTZ Burlington· 10 hours agoThe Food and Drug Administration’s committee of independent advisers voted unanimously Wednesday to...
New COVID-19 vaccine for fall should target JN.1 lineage, not variant, FDA panel
USA TODAY via Yahoo News· 1 day agoVaccine manufacturers Pfizer, Moderna and Novavax each told the panel they were prepared to make...
Adults 60+ Will Have 3 RSV Vaccines to Choose From This Year
Verywell Health via Yahoo News· 1 day agoThe FDA approved mRESVIA based on data from a clinical trial that included more than 35,000 adults...
New Covid Boosters Get a Thumbs-Up From FDA. Vaccine Stocks Are Wavering.
Barrons.com· 11 hours agoDrugmakers are aiming to launch this year’s shots by the beginning of September but have been...
US FDA approves Moderna’s RSV vaccine, its second marketed product
WHTC 1450 Holland· 6 days agoBy Patrick Wingrove (Reuters) - The U.S. Food and Drug Administration has approved Moderna's...
FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
Zacks via Yahoo Finance· 2 days agoAn FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to...
mRESVIA’s FDA approval paves the way for mRNA vaccines across multiple indications
Clinical Trials Arena via Yahoo Finance· 14 hours agovaccine to enter the US market following the launches of GSK’s Arexvy and Pfizer’s Abrysvo in 2023....
Is Moderna Stock A Buy As The U.S. Government Mulls Its Bird Flu Vaccine?
Investor's Business Daily· 7 days agovaccine in partnership with Merck. The shot prompts an immune response against a patient's own tumor...
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
Investor's Business Daily· 6 days agoAfter a median follow-up time of 112 days — roughly three to four months — the shot proved 83.7% ...
Moderna wins FDA approval for RSV vaccine
BioPharma Dive via Yahoo Finance· 7 days agoThe OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.